SCHEMBL19989510

SCHEMBL19989510

Cc1c(B2OC(C)(C)C(C)(C)O2)ccc2[nH]nc(N)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 4/20 0.36
GAA P10253 2/20 0.36
MAP2K1 Q02750 2/20 0.34
KDR P35968 5/20 0.33
KIT P10721 3/20 0.33
FLT3 P36888 3/20 0.33
JAK2 O60674 5/20 0.32
LCK P06239 3/20 0.32
CSF1R P07333 3/20 0.32
PRKACA P17612 3/20 0.32
ROCK1 Q13464 3/20 0.32
FGFR1 P11362 2/20 0.32
AURKA O14965 2/20 0.32
LYN P07948 2/20 0.32
SRC P12931 2/20 0.32
CDK2 P24941 2/20 0.32
BLK P51451 2/20 0.32
AURKB Q96GD4 2/20 0.32
MAP4K4 O95819 2/20 0.32
FLT1 P17948 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859433 1.00 PDPK1 (0.36) PDPK1GAAMAP2K1KDRKIT
SCHEMBL19989547 0.86 GAA (0.43) PDPK1GAAMAP2K1KDRKIT
SCHEMBL29859216 0.86 GAA (0.43) PDPK1GAAMAP2K1KDRKIT
SCHEMBL19989468 0.84 KDR (0.37) PDPK1GAAMAP2K1KDRKIT
SCHEMBL29859747 0.84 KDR (0.37) PDPK1GAAMAP2K1KDRKIT
SCHEMBL19989450 0.82 PDPK1 (0.34) PDPK1GAAMAP2K1KDRKIT
SCHEMBL29859572 0.82 PDPK1 (0.34) PDPK1GAAMAP2K1KDRKIT
SCHEMBL29859278 0.73 LPL (0.33) GAAKDRKITFLT3
SCHEMBL19989538 0.73 LPL (0.33) GAAKDRKITFLT3
SCHEMBL23208845 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 PDPK1 1841/4885GAA 4269/4885MAP2K1 2416/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 PDPK1 1649/4885GAA 3844/4885MAP2K1 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.